The gastrointestinal diagnostics market size is estimated to be USD 4,689.2 million in 2022 and is expected to witness a CAGR of 4.95% during the forecast period 2023-2033. Growing preference for POC testing for gastrointestinal disorders and surge in initiatives by government entities are factors contributing to the market growth. Additionally, rising incidence of gastrointestinal (GI) disorders and continuous regulatory approvals and product introduction of innovative diagnostic tests for gastrointestinal disorders is expected to propel the market growth. However, adverse effect of drugs is expected to hinder the growth.

Rising incidence of gastrointestinal (GI) disorders is expected to propel the market growth during the projected period. For instance, Bedfont Scientific Ltd. and GI Cognition collaborated in June 2021 to introduce cutting-edge methane and hydrogen testing home kits for remotely improving gastrointestinal health. This test kit enables remote testing of numerous gastrointestinal problems, including IBS, food intolerances, and other issues, which is anticipated to drive market expansion throughout the course of the forecast period.

Continuous regulatory approvals and product introduction of innovative diagnostic tests for gastrointestinal disorders is predicted to fuel the market growth during the forecast period. For instance, Biomerica, Inc. obtained the CE mark in May 2022 for their hp+detect diagnostic test for the identification of H. pylori bacteria in the European Union and other nations. The most frequent cause of stomach cancer risk is H. pylori bacteria.

Segmentation

By Test Type

The market is categorized into H. pylori test, immunoglobulin A test, blood test, endoscopy, calprotectin test, others. In the global market, the endoscopy segment accounted for the largest revenue share in 2022 owing to the rise in demand for minimally invasive procedures, high preference of medical professionals for endoscopic procedures, and technological developments. Additionally, it is projected that the increase in product launches to introduce innovative products with high precision will promote market growth. For instance, Fujifilm introduced the El-740D/S dual-channel endoscope in October 2021. This is the first dual-channel endoscope that the American FDA has approved for use in applications involving both the lower and upper gastrointestinal tracts. The blood test segment is expected to expand at the fastest rate over the projection period. The segment will be driven by rising acceptance of molecular testing and other blood-based diagnostics for the identification of gastrointestinal diseases.

By Technology

The market is divided into microbiology, PCR, ELISA, and others. In 2022, the PCR segment accounted for the highest revenue share due to growing use of PCR in diagnostic processes and the development of accurate, user-friendly point-of-care assays. Additionally, the segment’s expansion has been boosted by the existence of prominent market players who provide GI panel tests for a variety of gastrointestinal diseases. For instance, the BIOMERIEUX BioFire FilmArray Gastrointestinal Panel is a multiplex PCR technology that allows for precise, rapid automated testing for common GI pathogens including bacteria, viruses, and parasites that cause infectious diarrhoea. The ELISA segment is anticipated to grow at the fastest rate during the forecast period. Growth in the market is being supported by an increase in the use of immunoassay tests such as the Calprotectin ELISA test. Additionally, this technique’s key benefits, including quick detection and simplicity of use, are encouraging more people to do these tests.

By Application

The market is segregated into cancer, gastroesophageal reflux disease (GERD), inflammatory bowel disease, infection, others. In the global market, the infection segment accounted for the largest revenue share in 2022 owing to growing prevalence of GI infections such C. difficile, salmonella, shigella, and H. pylori, and the spike in GI infection diagnosis and rise in awareness. 1 in 6 Americans, according to the CDC, have C. difficile infection. In the upcoming years, the cancer segment is anticipated to increase at the fastest rate. Some of the major factors propelling the segment over the projected period include the rising incidence of colorectal cancers, government programmes to manage cancer, and technical improvements in the diagnosis of gastrointestinal cancer. For instance, there were more than 1.9 million colorectal cancer cases reported worldwide in 2020.

By Test Location

The market is segmented into point of care and central laboratories. In 2022, the central laboratories segment accounted for the largest revenue share owing to rapid test results, availability of many GI diagnostic facilities, and improvements in the healthcare infrastructure. Additionally, compared to PoC tests, laboratory-based tests are more accurate, which supports the segment’s growth. The point-of-care segment is anticipated to present a lucrative CAGR during the expected period. A competitive edge in the market is provided by factors such the growing demand for point-of-care testing, technological developments, quick turnaround times, and reduced complexity. Further predicted to boost segment growth is the introduction of high-tech endoscope equipment including laser speckle contrast imaging (LSCI) to study the gastrointestinal tracts.

Regional Markets

In 2022, North America region accounted for the highest revenue in the gastrointestinal diagnostics market and is expected to maintain its dominance during the forecast period. This is attributed to the high frequency of gastrointestinal disorders, growing public awareness of these conditions, and the presence of a cutting-edge healthcare infrastructure. Furthermore, the segment is expected to expand in the upcoming years due to the presence of major market competitors and their strategic activities. Asia Pacific is anticipated to have the fastest growth rate during the projection period. The existence of untapped market potential and a rise in demand for cost-effective diagnostic solutions both contribute to the expansion of the Asia-Pacific region. Furthermore, it is anticipated that the region’s growing geriatric population and huge patient pool will promote regional growth. Additionally, gastrointestinal diseases-related R&D initiatives will promote segment expansion. Over the previous ten years, the number of GI-related clinical trials has surged by 138%.

Competitor Insights

Some of the key players operating in the gastrointestinal diagnostics market are Beckman Coulter, Abbott, Inc., QIAGEN, BIOMERIEUX, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Meridian Bioscience, DiaSorin S.p.A, and Hologic, Inc.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Lyo-Ready sample-specific stool mixes were introduced by Meridian Bioscience, Inc. in June 2022 to facilitate diagnostic assay stabilization at room temperature and increase molecular detection.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including test type, technology, application, test location from 2023 to 2033.

Report Scope:

Segmentation: Gastrointestinal Diagnostics Market Report 2022 – 2033

Test Type (Revenue, USD Million), 2022 – 2033

• pylori Test
• Immunoglobulin A Test
• Blood Test
• Endoscopy
• Calprotectin Test
• Others

Technology (Revenue, USD Million), 2022 – 2033

• Microbiology
• PCR
• ELISA
• Others

Application (Revenue, USD Million), 2022 – 2033

• Cancer
• Gastroesophageal Reflux Disease (GERD)
• Inflammatory Bowel Disease
• Infection
• Others

Test Location (Revenue, USD Million), 2022 – 2033

• Point of Care
• Central Laboratories

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA